Clinical Study Of Schizophrenia in Both Men and Women

• Status: Completed
• Trial end date: 2005-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The objective of this study is to evaluate the effectiveness of a marketed drug in the treatment of schizophrenia, as an add-on therapy to antipsychotics over a 12-week period. Subjects with schizophrenia who have been maintained on a stable dose of antipsychotics and who fulfill the screening entrance criteria will have an assessment 1-7 days after the first visit to confirm eligibility.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: Anticonvulsants; Lamotrigine

Criteria

Inclusion criteria:

• If female, must not be pregnant, or must be incapable of conceiving or be taking steps to prevent conception.

• Diagnosis of Schizophrenia

• Patients must be taking clozapine monotherapy or other atypical antipsychotic at least 3 months prior to this study.

Exclusion criteria:

• Patients who are currently taking or have taken antidepressant medication in the last month prior.

• Patients who are or have been suicidal or homicidal in the last 6 months.

• Patients with a history of autistic disorder or another pervasive developmental disorder

• Patients whose condition is due to the direct physiological effects of a substance (e.g. a drug of abuse, a medication) or a general medical condition